Cerus Free Cash Flow 2010-2024 | CERS
Cerus free cash flow from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Cerus Annual Free Cash Flow | |
|---|---|
| 2023 | -47.77 |
| 2022 | -27.62 |
| 2021 | -34.83 |
| 2020 | -43.43 |
| 2019 | -74.43 |
| 2018 | -32.39 |
| 2017 | -52.59 |
| 2016 | -54.09 |
| 2015 | -51.85 |
| 2014 | -41.89 |
| 2013 | -27.33 |
| 2012 | -14.00 |
| 2011 | -15.74 |
| 2010 | -15.97 |
| 2009 | -14.70 |
| Cerus Quarterly Free Cash Flow | |
|---|---|
| 2024-09-30 | 4.57 |
| 2024-06-30 | 1.22 |
| 2024-03-31 | 0.86 |
| 2023-12-31 | -47.77 |
| 2023-09-30 | -32.59 |
| 2023-06-30 | -19.46 |
| 2023-03-31 | -10.02 |
| 2022-12-31 | -27.62 |
| 2022-09-30 | -24.62 |
| 2022-06-30 | -21.99 |
| 2022-03-31 | -21.57 |
| 2021-12-31 | -34.83 |
| 2021-09-30 | -33.15 |
| 2021-06-30 | -26.34 |
| 2021-03-31 | -17.65 |
| 2020-12-31 | -43.43 |
| 2020-09-30 | -34.06 |
| 2020-06-30 | -28.63 |
| 2020-03-31 | -20.25 |
| 2019-12-31 | -74.43 |
| 2019-09-30 | -65.74 |
| 2019-06-30 | -41.58 |
| 2019-03-31 | -25.49 |
| 2018-12-31 | -32.39 |
| 2018-09-30 | -24.78 |
| 2018-06-30 | -19.40 |
| 2018-03-31 | -10.38 |
| 2017-12-31 | -52.59 |
| 2017-09-30 | -42.55 |
| 2017-06-30 | -29.70 |
| 2017-03-31 | -16.53 |
| 2016-12-31 | -54.09 |
| 2016-09-30 | -44.18 |
| 2016-06-30 | -27.69 |
| 2016-03-31 | -13.09 |
| 2015-12-31 | -51.85 |
| 2015-09-30 | -42.91 |
| 2015-06-30 | -30.81 |
| 2015-03-31 | -15.81 |
| 2014-12-31 | -41.89 |
| 2014-09-30 | -33.21 |
| 2014-06-30 | -20.87 |
| 2014-03-31 | -10.66 |
| 2013-12-31 | -27.33 |
| 2013-09-30 | -20.57 |
| 2013-06-30 | -14.22 |
| 2013-03-31 | -8.38 |
| 2012-12-31 | -14.00 |
| 2012-09-30 | -11.14 |
| 2012-06-30 | -9.35 |
| 2012-03-31 | -3.91 |
| 2011-12-31 | -15.74 |
| 2011-09-30 | -14.67 |
| 2011-06-30 | -11.11 |
| 2011-03-31 | -5.11 |
| 2010-12-31 | -15.97 |
| 2010-09-30 | -11.90 |
| 2010-06-30 | -9.07 |
| 2010-03-31 | -5.96 |
| 2009-12-31 | -14.70 |
| 2009-09-30 | -11.93 |
| 2009-06-30 | -9.81 |
| 2009-03-31 | -7.20 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.293B | $0.156B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $194.797B | 24.85 |
| Boston Scientific (BSX) | United States | $139.837B | 40.20 |
| Stryker (SYK) | United States | $139.395B | 31.41 |
| EssilorLuxottica (ESLOY) | France | $110.104B | 0.00 |
| Medtronic (MDT) | Ireland | $103.429B | 15.36 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.664B | 0.00 |
| Haleon (HLN) | United Kingdom | $41.193B | 26.76 |
| GE HealthCare Technologies (GEHC) | United States | $38.725B | 20.09 |
| ResMed (RMD) | United States | $34.324B | 28.21 |
| Terumo (TRUMY) | Japan | $28.025B | 39.58 |
| Koninklijke Philips (PHG) | Netherlands | $24.269B | 18.58 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.811B | 13.25 |
| Insulet (PODD) | United States | $19.068B | 75.93 |
| Baxter (BAX) | United States | $15.022B | 9.77 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.471B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.568B | 32.52 |
| BellRing Brands (BRBR) | United States | $9.145B | 36.79 |
| Demant (WILYY) | Denmark | $8.596B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.666B | 15.49 |
| Haemonetics (HAE) | United States | $3.851B | 18.79 |
| ICU Medical (ICUI) | United States | $3.779B | 35.98 |
| Prestige Consumer Healthcare (PBH) | United States | $3.656B | 18.18 |
| Perrigo (PRGO) | Ireland | $3.326B | 9.79 |
| Envista Holdings (NVST) | United States | $3.198B | 23.82 |
| QuidelOrtho (QDEL) | United States | $3.077B | 19.81 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| Neogen (NEOG) | United States | $2.678B | 30.90 |
| GN Store Nord (GNNDY) | Denmark | $2.593B | 16.63 |
| LeMaitre Vascular (LMAT) | United States | $2.104B | 51.14 |
| Green Thumb Industries (GTBIF) | United States | $1.564B | 27.37 |
| AtriCure (ATRC) | United States | $1.531B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.364B | 9.75 |
| InMode (INMD) | Israel | $1.335B | 8.03 |
| BioLife Solutions (BLFS) | United States | $1.234B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.225B | 0.00 |
| Owens & Minor (OMI) | United States | $1.071B | 8.37 |
| Curaleaf Holdings (CURLF) | Canada | $0.942B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.812B | 14.32 |
| CeriBell (CBLL) | United States | $0.750B | 0.00 |
| Evolus (EOLS) | United States | $0.633B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.600B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.551B | 24.31 |
| Surmodics (SRDX) | United States | $0.549B | 0.00 |
| Omeros (OMER) | United States | $0.512B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.459B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.423B | 0.00 |
| ZimVie (ZIMV) | United States | $0.372B | 31.37 |
| Valneva SE (VALN) | France | $0.369B | 0.00 |
| Quanterix (QTRX) | United States | $0.363B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.310B | 29.44 |
| Biote (BTMD) | United States | $0.307B | 6.73 |
| Sanara MedTech (SMTI) | United States | $0.282B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.270B | 18.10 |
| Canopy Growth (CGC) | Canada | $0.267B | 0.00 |
| High Tide (HITI) | Canada | $0.250B | 103.00 |
| Zynex (ZYXI) | United States | $0.249B | 52.20 |
| Aurora Cannabis (ACB) | Canada | $0.227B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.224B | 3.15 |
| Utah Medical Products (UTMD) | United States | $0.207B | 14.26 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.198B | 0.00 |
| Brainsway (BWAY) | Israel | $0.177B | 94.00 |
| TerrAscend (TSNDF) | Canada | $0.164B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.157B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.137B | 17.21 |
| Quipt Home Medical (QIPT) | United States | $0.129B | 0.00 |
| Jin Medical (ZJYL) | China | $0.126B | 0.00 |
| Veru (VERU) | United States | $0.114B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.88 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.096B | 0.00 |
| InterCure (INCR) | Israel | $0.076B | 0.00 |
| INLIF (INLF) | $0.068B | 0.00 | |
| Rockwell Medical (RMTI) | United States | $0.067B | 34.67 |
| Apyx Medical (APYX) | United States | $0.060B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| Exagen (XGN) | United States | $0.056B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.052B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.051B | 0.00 |
| ImmuCell (ICCC) | United States | $0.046B | 0.00 |
| Modular Medical (MODD) | United States | $0.046B | 0.00 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 13.30 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |